Dongxu Qiu

Beijing, 100730, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

High-gradient magnetic separation chip-based small extracellular vesicle isolation for noninvasive subtyping of primary aldosteronism.

High-gradient magnetic separation chip-based small extracellular vesicle isolation for noninvasive subtyping of primary aldosteronism.

Journal: Science advances

Published: April 17, 2026

Evaluation of ChatGPT-4o's and DeepSeek R1's responses to urological problems: a comparative study.

Evaluation of ChatGPT-4o's and DeepSeek R1's responses to urological problems: a comparative study.

Journal: BMC urology

Published: March 02, 2026

Renal Function Outcomes in Tuberous Sclerosis Complex Patients Receiving Everolimus for Renal Angiomyolipoma.

Renal Function Outcomes in Tuberous Sclerosis Complex Patients Receiving Everolimus for Renal Angiomyolipoma.

Journal: European urology open science

Published: December 13, 2025

Single-cell RNA sequencing reveals the potential role of estrogen in tuberous sclerosis complex related renal angiomyolipoma.

Single-cell RNA sequencing reveals the potential role of estrogen in tuberous sclerosis complex related renal angiomyolipoma.

Journal: Discover oncology

Published: February 06, 2025

Benign pure androgen-secreting adrenal tumor misdiagnosed as adrenocortical carcinoma on 18F-FDG PET-CT: a rare case report.

Benign pure androgen-secreting adrenal tumor misdiagnosed as adrenocortical carcinoma on 18F-FDG PET-CT: a rare case report.

Journal: Endocrine

Published: August 14, 2024

The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex.

The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex.

Journal: Discover oncology

Published: May 23, 2024

PMEL is a predictive biomarker for mTORC1 inhibitor treatment of renal angiomyolipoma in tuberous sclerosis complex patients.

PMEL is a predictive biomarker for mTORC1 inhibitor treatment of renal angiomyolipoma in tuberous sclerosis complex patients.

Journal: Heliyon

Published: March 10, 2024

New staging criteria predicting m-tor inhibitors treatment effect of renal angiomyolipoma in tuberous sclerosis complex patients.

New staging criteria predicting m-tor inhibitors treatment effect of renal angiomyolipoma in tuberous sclerosis complex patients.

Journal: World journal of urology

Published: December 13, 2023

The predictive value of PFKFB3 in bladder cancer prognosis.

The predictive value of PFKFB3 in bladder cancer prognosis.

Journal: Heliyon

Published: July 28, 2023

The association between computed tomography attenuation value of renal angiomyolipoma associated with tuberous sclerosis complex and response to everolimus.

The association between computed tomography attenuation value of renal angiomyolipoma associated with tuberous sclerosis complex and response to everolimus.

Journal: World journal of urology

Published: April 20, 2023

Showing 1-10 of 10

Last Updated: 09/26/2026